High Gene-Therapy Costs Trigger Call for New Payment Models

The six-figure prices of new gene therapies will require payers, pharma companies, policymakers, and pharmacy benefit managers (PBMs) to develop new payment models that ensure patient access while reflecting the value delivered by the new treatments based on clinical outcomes, a top executive with PBM Express Scripts asserts.“Gene therapies will require payment and patient care systems that are as novel as the medications themselves,” Express Scripts CMO Steve Miller, M.D., wrote in